pMP31-1 Citations (3)
Originally described in: Convergent evolution of escape from hepaciviral antagonism in primates.Patel MR, Loo YM, Horner SM, Gale M Jr, Malik HS PLoS Biol. 2012;10(3):e1001282. doi: 10.1371/journal.pbio.1001282. Epub 2012 Mar 13. PubMed Journal
Articles Citing pMP31-1
Articles |
---|
Rotavirus VP3 targets MAVS for degradation to inhibit type III interferon expression in intestinal epithelial cells. Ding S, Zhu S, Ren L, Feng N, Song Y, Ge X, Li B, Flavell RA, Greenberg HB. Elife. 2018 Nov 21;7. pii: 39494. doi: 10.7554/eLife.39494. PubMed |
Metabolic Control of Astrocyte Pathogenic Activity via cPLA2-MAVS. Chao CC, Gutierrez-Vazquez C, Rothhammer V, Mayo L, Wheeler MA, Tjon EC, Zandee SEJ, Blain M, de Lima KA, Takenaka MC, Avila-Pacheco J, Hewson P, Liu L, Sanmarco LM, Borucki DM, Lipof GZ, Trauger SA, Clish CB, Antel JP, Prat A, Quintana FJ. Cell. 2019 Dec 12;179(7):1483-1498.e22. doi: 10.1016/j.cell.2019.11.016. Epub 2019 Dec 5. PubMed |
Conserved Functions of Orthohepadnavirus X Proteins to Inhibit Type-I Interferon Signaling. Choonnasard A, Shofa M, Okabayashi T, Saito A. Int J Mol Sci. 2024 Mar 28;25(7):3753. doi: 10.3390/ijms25073753. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.